Bank Of America Corp Immuno Gen, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $4.56 Million - $11 Million	366,101 Added 88.39%	780,279 $23.1 Million
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $5.46 Million - $29.2 Million	-1,454,845 Reduced 77.84%	414,178 $7.82 Million
Q1 2023 May 12, 2023	BUY	$3.67 - $4.92 $785,926 - $1.05 Million	214,149 Added 12.94%	1,869,023 $7.18 Million
Q4 2022 Feb 10, 2023	BUY	$4.55 - $6.31 $2.13 Million - $2.96 Million	468,537 Added 39.49%	1,654,874 $8.21 Million
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $1.43 Million - $2.06 Million	-318,912 Reduced 21.19%	1,186,337 $5.67 Million
Q2 2022 Aug 12, 2022	BUY	$3.15 - $5.76 $141,173 - $258,145	44,817 Added 3.07%	1,505,249 $6.77 Million
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $1.6 Million - $2.82 Million	376,567 Added 34.74%	1,460,432 $6.95 Million
Q4 2021 Feb 08, 2022	BUY	$4.75 - $7.5 $1.55 Million - $2.44 Million	325,868 Added 42.99%	1,083,865 $8.04 Million
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $22,153 - $29,081	4,413 Added 0.59%	757,997 $4.3 Million
Q2 2021 Sep 13, 2021	BUY	$5.79 - $8.6 $4.36 Million - $6.48 Million	753,584 New	753,584 $4.97 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.